News Dimerix Limited

Equities

DXB

AU000000DXB7

Market Closed - Australian S.E. Other stock markets 11:40:11 03/05/2024 am IST			5-day change	1st Jan Change
0.36 ^AUD	+7.46%		+12.50%	+75.61%

01/05	Dimerix Secures Pediatric Plan Approval in the UK for Kidney Disease Medication	MT
22/04	Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dimerix Secures Pediatric Plan Approval in the UK for Kidney Disease Medication	01/05	MT
Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter	23/04	MT
Euroz Hartleys Starts Dimerix at Speculative Buy With AU$0.80 Price Target	19/04	MT
Dimerix Raises AU$20 Million for Kidney Disease Study	12/03	MT
Dimerix Expanding Kidney Drug Study After DMX-200 Performs Better than Placebo	11/03	MT
Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2023	26/02	CI
Dimerix Limited Announces Appointment of Mark Diamond as Director	01/12	CI
Dimerix Secures Investigational New Drug Approval for Kidney Disease Medication in China; Shares Rally 11%	28/11	MT
Dimerix Appoints Nonexecutive Chair	20/11	MT
Dimerix Receives AU$10.7 Million Upfront Payment for Commercialization Rights	07/11	MT
Dimerix Appoints Medical Chief	23/23/23	MT
Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer	23/23/23	CI
ADVANZ PHARMA and Dimerix enter into an Exclusive License Agreement to commercialise DMX-200 in Europe, Canada, Australia, and New Zealand	05/23/05	AQ
Softer US Employment Data End Australian Shares' Three-Day Losing Streak	05/23/05	MT
Dimerix Surges 154% After Securing License Deal for Kidney Disease Drug	05/23/05	MT
Dimerix Secures Conditional US FDA Clearance for Kidney Medication Brand Name	25/23/25	MT
Dimerix Secures Regulatory Nod to Conduct Kidney Disease Drug Trial in Malaysia	22/23/22	MT
Dimerix Secures AU$9 Million R&D Tax Rebate; Shares Rise 3%	13/23/13	MT
Dimerix Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/23/30	CI
Dimerix Secures Approval for Pediatric Kidney Disease Plan in Europe	05/23/05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Dimerix Limited

Equities

DXB

AU000000DXB7

Summary

Filters